No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MTNB Matinas BioPharma
- 0.1818
- +0.0003+0.17%
Close Apr 24 16:00 ET
- 0.1819
- +0.0001+0.06%
Post 19:58 ET
45.60MMarket Cap-1652P/E (TTM)
0.1850High0.1772Low521.89KVolume0.1808Open0.1815Pre Close94.29KTurnover0.21%Turnover RatioLossP/E (Static)250.82MShares0.890052wk High2.36P/B44.44MFloat Cap0.110352wk Low--Dividend TTM244.44MShs Float3.9500Historical High--Div YieldTTM4.30%Amplitude0.1103Historical Low0.1800Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Matinas BioPharma's Multi-Million Share Sale and Lock-Up Deal
Express News | Matinas BioPharma Prices $10M Registered Direct Offering At A Combined Offering Price Of $0.30 Per Share And Accompanying Warrant
Matinas BioPharma Prices $10 Million Registered Direct Offering
BEDMINSTER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) ("Matinas BioPharma" or the "Company"), a clinical-stage biopharmaceutical company focused on delivering groundbreaking
Matinas BioPharma (MTNB) Gets a Buy From Maxim Group
12 Health Care Stocks Moving In Monday's After-Market Session
GainersOpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. The market value of their outstanding shares is at $7.4 million. Galecto (NASDAQ:GLTO) shares in
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript
Comments
Just a bit of info!
$Matinas BioPharma(MTNB.US$ Key Program Updates MAT2203 (Oral Amphotericin B) Program Phase 3 ORALTO Registration Trial ● Matinas reached alignment with the FDA on the design of a single Phase 3 registration trial of oral MAT2203 in patients with invasive aspergillosis who have limited treatment options. This is a serious and life-threatening invasive fungal infection that occurs primarily in severely immunocompromised patients, including those with hematological malignancies...
4
Update
$Matinas BioPharma(MTNB.US$ Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
1 MINUTE AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel
Results build on data from prior in vivo study of oral LNC-docetaxel showing reductions in tumor size comparable to IV-doce...
1 MINUTE AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel
Results build on data from prior in vivo study of oral LNC-docetaxel showing reductions in tumor size comparable to IV-doce...
1
5
$Matinas BioPharma(MTNB.US$ My final scale is .4013!
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Jaguar8 : We need this medication. Alert to shorters!
TrytosaveabitOP Jaguar8: Yes sir 100% correct! But you really think that most SS’s give two s*its! As long as they make a few bucks who cares if they have to bankrupt a company doing great things for so many in need! Sad but true my friend
Jaguar8 TrytosaveabitOP: I know and they will suffer the wrath of karma
TrytosaveabitOP Jaguar8: Yup